Paragon 28 Is Maintained at Buy by Canaccord Genuity
Piper Sandler Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $12
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Cuts Target Price to $15
BofA Securities Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $12
Paragon 28 Analyst Ratings
Needham Maintains Paragon 28(FNA.US) With Buy Rating, Raises Target Price to $13
JMP Securities Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $20
Buy Rating on Paragon 28: Strong Financial Performance, Strategic Initiatives, and Niche Market Success
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Paragon 28 (FNA)
Paragon 28 Analyst Ratings
Buy Rating Affirmed for Paragon 28 Amid Strong Financial Performance and Strategic Growth
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $17
Paragon 28 Analyst Ratings
Paragon 28 (FNA) Gets a Buy From Piper Sandler
Paragon 28 Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Paragon 28's Sustained Growth and Strategic Initiatives Bolster Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)